Metra M, Teerlink JR, Cotter G, et al. - Researchers performed a multicenter, double-blind, placebo-controlled, event-driven trial investigating the effect of serelaxin treatment on symptom relief and outcomes in 6,545 patients with acute heart failure. They administered a 48-hour intravenous infusion of either serelaxin (30 μg per kilogram of body weight per day) or placebo in combination with standard care in patients hospitalized for acute heart failure and had dyspnea, vascular congestion on chest radiography, increased plasma concentrations of natriuretic peptides, mild-to-moderate renal insufficiency, and a systolic blood pressure of at least 125 mmHg, within 16 hours after presentation. Outcomes revealed no lower incidence of death from cardiovascular causes at 180 days or worsening heart failure at 5 days in this trial following an infusion of serelaxin vs placebo.